Fiche publication
Date publication
mai 2024
Journal
Future medicinal chemistry
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MORJANI Hamid
Tous les auteurs :
Oubella A, Alossaimi MA, Riadi Y, Bhat MA, Bakheit AH, Taha ML, Auhmani A, Morjani H, Geesi MH, Ait Itto MY
Lien Pubmed
Résumé
This study explores the cytotoxic and apoptotic effects of novel thiazolidinone-1,2,3-triazole hybrids on HT-1080, A-549, and MDA-MB-231 cancer cell lines. The synthesized compounds underwent comprehensive characterization (NMR and HRMS) to confirm their structures and purity. Subsequent anticancer activity screening across diverse cancer cell lines revealed promising antitumor potential notably, compounds and . Mechanistic investigations unveiled that compound triggers apoptosis through the caspase-3/7 pathway. In terms of studies, the compound was identified as a potent inhibitor of caspase-3 and caspase-7. The present study underscores the therapeutic potential of thiazolidinone-1,2,3-triazole hybrids against certain cancer cells. These findings highlight a promising avenue for the development of cancer treatment strategies utilizing these (R)-Carvone-based derivatives.
Mots clés
(R)-Carvone, apoptosis, cancer, cytotoxic activity, molecular docking, thiazolidinone
Référence
Future Med Chem. 2024 05 30;16(14):1449-1464
